A second stimulus originated from the introduction of PSMA targeting ligands for diagnosis and therapy in prostate cancer.3 [68Ga]Ga ‐PSMA ‐114 has proven to be a highly sensitive and specific marker for early detection and localization of prostate lesions in the biochemical recurrence stage and other clinical indications. Here, FOLH1 is linked to prostate carcinoma.